Shots:
- The P-Ib/IIa trial assessed amycretin (Q1W) vs PBO in overweight or obese patients (n=125) in 5 parts
- Part A (single ascending dose) assessed PK & determined the initial dose for Part B (multiple dose arm), which evaluated safety/tolerability over 36wks. Parts C, D, & E (PoC) evaluated weight loss with 3 doses (1.25mg, 5mg, & 20mg) over 12wks. each
- Data showed Amycretin-treated patients achieved a weight loss of 9.7% (1.25mg, 20 wks.), 16.2% (5mg, 28wks.), & 22.0% (20 mg, 36wks.) from a 92.7kg (baseline), while PBO-treated patients gained weight (~1.9%, 2.3% & 2.0%). Results demonstrated weight lowering potential based on which Novo to plan further clinical development
Ref: Globenewswire | Image: Novo Nordisk
Related News:- Novo Nordisk Reports Headline Results from P-IIIb (STEP UP) Study of Semaglutide 7.2mg in Obese Adults without Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
